Oncology

Back to articles

Pegfilgrastim Provides Extended Duration for Managing Neutropenia

KEY POINT

Pegfilgrastim (Neulasta—Amgen) has been approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving chemotherapy. While it carries nearly the same indication as the company’s well-known filgrastim (Neupogen) colony-stimulating factor, the pegylated form of the drug has a longer half-life, which permits a single subcutaneous (SC) injection 24 hours after chemotherapy that will stimulate hematopoiesis for up to 14 days.

SOURCES

Holmes FA et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as a adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–31.